—Data Presented at the CHEST 2024 Annual Meeting— BRIDGEWATER, N.J. , Oct.
8, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today presented positive late-breaking subgroup data from the Phase 3 ASPEN study, a global, randomized, double-blind, placebo-controlled Phase 3 study to assess the efficacy, safety, and tolerability of brensocatib in patients with non-cystic fibrosis bronchiectasis. Posters with the details from these subgroup analyses can be found HERE . These data were presented at the CHEST 2024 Annual Meeting, held October 6-9 in Boston , along with several other presentations from across Insmed's respiratory portfolio.
"The positive results from the landmark Phase 3 ASPEN study have generated tremendous excitement among physicians and patients alike, providing hope for a much-needed approved treatment for bronchiectasis. Given the heterogeneity of this disease, it is striking that these new sub-analyses show a consistent positive impact on the rate of exacerbations across the majority of prespecified subgroups," said lead study investigator James Chalmers , MBChB, Ph.D.
, Professor and Consultant Respiratory Physician at the School of Medicine, University of Dundee , UK. "It is particularly exciting to see that, consistent with the overall trial analysis, brensocatib 25 mg was able to slow.
